1. Home
  2. TSLX vs VIR Comparison

TSLX vs VIR Comparison

Compare TSLX & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sixth Street Specialty Lending Inc.

TSLX

Sixth Street Specialty Lending Inc.

HOLD

Current Price

$16.59

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

HOLD

Current Price

$9.35

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSLX
VIR
Founded
2010
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
2011
2019

Fundamental Metrics

Financial Performance
Metric
TSLX
VIR
Price
$16.59
$9.35
Analyst Decision
Buy
Strong Buy
Analyst Count
9
7
Target Price
$21.61
$19.43
AVG Volume (30 Days)
736.3K
2.4M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
10.82%
N/A
EPS Growth
N/A
17.49
EPS
N/A
N/A
Revenue
N/A
$68,556,000.00
Revenue This Year
N/A
$270.22
Revenue Next Year
$1.20
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.04
$4.16
52 Week High
$24.79
$11.66

Technical Indicators

Market Signals
Indicator
TSLX
VIR
Relative Strength Index (RSI) 41.55 44.24
Support Level $16.04 $8.40
Resistance Level $18.05 $10.10
Average True Range (ATR) 0.41 0.42
MACD -0.03 -0.10
Stochastic Oscillator 0.19 9.52

Price Performance

Historical Comparison
TSLX
VIR

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

Share on Social Networks: